Trials / Terminated
TerminatedNCT03762681
A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection
A Randomized, Placebo-controlled,Observer-blinded Study, to Evaluate Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of RO7239958 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses in healthy volunteers (HV) and participants diagnosed with chronic hepatitis B (CHB).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7239958 | Solution for injection, subcutaneous use (SC). |
| OTHER | Placebo | Sodium chloride solution for injection, SC |
Timeline
- Start date
- 2018-12-14
- Primary completion
- 2020-04-06
- Completion
- 2020-04-06
- First posted
- 2018-12-04
- Last updated
- 2021-05-11
- Results posted
- 2021-04-09
Locations
14 sites across 7 countries: Bulgaria, Hong Kong, New Zealand, Poland, South Korea, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT03762681. Inclusion in this directory is not an endorsement.